It’s the prices, HHS OIG says

A report from the HHS Office of Inspector General on Medicare Part D prices provides ammunition for HHS Secretary Alex Azar’s attempts to reduce list prices. It could also hurt PhRMA’s efforts to persuade Congress to rescind an increase in drug company liability for

Read the full 449 word article

User Sign In